Home Cart Sign in  
Chemical Structure| 5291-32-7 Chemical Structure| 5291-32-7

Structure of Eprenetapopt
CAS No.: 5291-32-7

Chemical Structure| 5291-32-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

APR-246, is a small organic molecule that has been shown to restore tumour-suppressor function primarily to mutant p53 and also to induce cell death in various cancer types.

Synonyms: PRIMA-1Met; APR-246; APR 246. PRIMA-1MET

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eprenetapopt

CAS No. :5291-32-7
Formula : C10H17NO3
M.W : 199.25
SMILES Code : O=C1C(COC)(CO)N2CCC1CC2
Synonyms :
PRIMA-1Met; APR-246; APR 246. PRIMA-1MET
MDL No. :MFCD16294187
InChI Key :BGBNULCRKBVAKL-UHFFFAOYSA-N
Pubchem ID :52918385

Safety of Eprenetapopt

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Recombinant rat TrxR1 50 µM 10 minutes APR-246 inhibits TrxR1 activity, with MQ and preheated APR-246 being more potent inhibitors. PMC3920950
SKBR-3 40 μM 12 hours APR-246 repressed the expression of immune checkpoint molecules PMC9681866
MDAMB-231 200 μM 12 hours APR-246 repressed the expression of immune checkpoint molecules PMC9681866
MDAMB-468 60 μM 12 hours APR-246 repressed the expression of immune checkpoint molecules PMC9681866
BT-20 100 μM 12 hours APR-246 enhanced the expression of IFN signalling genes PMC9681866
BT-549 40 μM 12 hours APR-246 enhanced the expression of IFN signalling genes PMC9681866
OACM5.1 cells 50 µM 12 hours To study the effect of Eprenetapopt on cellular metabolism, results showed that Eprenetapopt decreased reduced GSH levels without increasing oxidized GSH (GSSG) levels, indicating total GSH depletion. PMC9473576
MOLM14 60 μM 16 hours To investigate the mechanisms underlying APR-246-induced cell death, results showed that iron chelators and lipophilic antioxidants almost completely rescued cell viability, indicating that cell death is both iron and ROS-dependent. PMC8804578
OVCAR-3 0.0025, 0.01, 0.05, 0.2, 0.8, 3.1, 12.5 µM 2 hours MS-CETSA data indicated that ASNS is a direct or indirect target of APR-246 via the active product MQ. MQ treatment resulted in increased thermal stability of ASNS, suggesting that MQ may directly or indirectly affect ASNS activity. PMC8282662
CCRF-CEM 10, 15 µM 2 hours WB-CETSA results showed that MQ treatment induced a temperature-dependent stabilization of ASNS at 57 and 59 °C, indicating that MQ directly or indirectly modulates ASNS. PMC8282662
DLD-1 90 μM 24 hours APR-246 enhanced the expression of IFN signalling genes PMC9681866
Neuroblastoma cell lines 16.1 μM 24 hours To investigate the ability of PRIMA-1MET to induce NB cell death, results showed that PRIMA-1MET induces cell death at low concentrations PMC6373164
Keratinocytes 65.8 μM (IC50) 24 hours To compare the specificity of PRIMA-1MET for tumor cells versus normal cells, results showed that normal cells are less sensitive to PRIMA-1MET PMC6373164
Fibroblasts 78.3 μM (IC50) 24 hours To compare the specificity of PRIMA-1MET for tumor cells versus normal cells, results showed that normal cells are less sensitive to PRIMA-1MET PMC6373164
H1299 cells 50 µM 24 hours To investigate whether Eprenetapopt-induced cell death could be reversed by ferroptosis inhibitors, results showed that ferroptosis inhibitors could reverse Eprenetapopt-induced cell death. PMC9473576
HL60 11 μM to >200 μM 24 hours To evaluate the activity of APR-246 in AML cells, results showed that most AML cell lines and primary AML cells were sensitive to cell death induction by APR-246. PMC8804578
TE1 10.5 μM 48 hours APR-246 induced significant apoptosis by upregulating p73 and Noxa via ROS induction in ESCC cell lines harbouring p53 missense mutations. PMC8608903
KYSE410 31.6 μM 48 hours APR-246 showed minimal effectiveness in ESCC with wild-type p53, and did not significantly induce apoptosis. PMC8608903
FLO-1 25 µM(GI90) 6 h To detect intracellular ROS levels after APR-246 treatment, results showed that APR-246 significantly increased ROS levels in FLO-1 cells. PMC5379068
JH-EsoAd1 40 µM(GI90) 6 h To detect intracellular ROS levels after APR-246 treatment, results showed that APR-246 significantly increased ROS levels in JH-EsoAd1 cells. PMC5379068
Keratinocytes from EEC syndrome patients 10–30 μM 7 days APR-246 partially restored differentiation defects in p63 mutant keratinocytes PMC3568378
UMSCC10A 0-50 μM 72 hours To evaluate the effect of APR-246 combined with PL on HNSCC cells, the results showed that the combination significantly reduced cell viability and increased cell death. PMC6014869
FaDu 0-50 μM 72 hours To evaluate the effect of APR-246 combined with PL on HNSCC cells, the results showed that the combination significantly reduced cell viability and increased cell death. PMC6014869
A2780-CP20 8 µM, 20 µM, 30 µM, 40 µM, 60 µM 72 hours APR-246 completely restored the sensitivity of ovarian cancer cells to cisplatin at clinically relevant concentrations. PMC4669826
OVCAR-3 2 µM, 20 µM, 30 µM 72 hours APR-246 resensitized OVCAR-3 cells to cisplatin and increased the efficacy of cisplatin. PMC4669826
neuroblastoma cells 3.8 μM 96 hours To assess the cytotoxicity of APR-246 on ALT cells, results showed ALT cells were significantly more sensitive to APR-246 PMC9566554
rhabdomyosarcoma cells 3.8 μM 96 hours To assess the cytotoxicity of APR-246 on ALT cells, results showed ALT cells were significantly more sensitive to APR-246 PMC9566554
carcinoma cells 3.8 μM 96 hours To assess the cytotoxicity of APR-246 on ALT cells, results showed ALT cells were significantly more sensitive to APR-246 PMC9566554

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice UMSCC10A xenograft model intraperitoneal injection 100 mg/kg/day daily for 24 days To evaluate the effect of APR-246 combined with PL on HNSCC xenograft tumors, the results showed that the combination significantly suppressed tumor growth. PMC6014869
Mice A2780-CP20 tumor xenograft model Intravenous injection 400 mg/kg/day APR-246: once daily for 7 days; cisplatin: once on day 2 and day 6 APR-246 in combination with cisplatin significantly inhibited tumor growth, indicating at least an additive effect. PMC4669826
C57BL/6J mice B16 melanoma model Intraperitoneal injection 100 mg/kg Daily for 6 days To study the effects of APR-246 on p53 expression in the tumor microenvironment and its combination with immune checkpoint blockade PMC9479603
Mice FLO-1 xenograft model Intraperitoneal injection 100 mg/kg Once daily for 3 weeks To evaluate the anti-tumour activity of APR-246 in the FLO-1 xenograft model, results showed that APR-246 significantly inhibited tumour growth. PMC5379068
BALB/C mice MCO4 fibrosarcoma model Intraperitoneal injection 100 mg/kg Daily for 4 days APR-246 promoted CD4+ T cells infiltration and decreased the exhaustion of CD8+ T cells in vivo PMC9681866
Athymic nu/nu mice xenograft model intraperitoneal injection 250 mg/kg twice daily for 7 days, 21-day cycle, total of 3 cycles To evaluate the efficacy of APR-246 combined with irinotecan in ALT xenograft models, results showed complete responses in ALT models PMC9566554
Mice Xenograft model Intraperitoneal injection 25 mg/kg/day Once daily for 21 days Combination of APR-246 and 5-FU showed synergistic antitumour effects in p53 missense mutant ESCC xenograft models through activation of ROS and the p73-Noxa pathway. PMC8608903
NSG mice FLO-1 LM tumor model intraperitoneal injection 100 mg/kg daily for 35 days To study the effect of Eprenetapopt combined with serine and glycine dietary restriction on tumor growth, results showed that the combination significantly inhibited primary tumor growth and delayed the onset of metastatic disease. PMC9473576
Mice Eso26 esophageal cancer cell xenograft model intraperitoneal injection 50 mg/kg APR-246, 50 mg/kg MK-571 APR-246 daily for 16 days; MK-571 daily except on days 6–7 and 13–14 Combination treatment with APR-246 and MK-571 significantly suppressed the growth of Eso26 xenograft tumors and prolonged the survival of mice. PMC7863383
NOD/SCID IL-2 receptor γ-chain-null mice MOLM14 xenograft model Intraperitoneal injection 100 mg/kg Once daily for 4 days To evaluate the synergistic anti-leukemic activity of APR-246 combined with SLC7A11 inhibition, results showed that SLC7A11 knockdown significantly reduced tumor cell burden in the BM, and this effect was enhanced when combined with APR-246 treatment. PMC8804578

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00900614 Hematologic Neoplasms|Prostati... More >>c Neoplasms Less << PHASE1 COMPLETED 2025-10-10 Section of Haematology and Coa... More >>gulation, Sahlgrenska University Hospital, G?teborg, 41345, Sweden|Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, SE 141 86, Sweden|Clinical Research and Development Unit, Department of Oncology, Akademiska Hospital, Uppsala, 75185, Sweden|Department of Haematology, Akademiska Hospital, Uppsala, 75185, Sweden|Department of Hematology, University Hospital, ?rebro, 70185, Sweden|Urology clinic, University Hospital, ?rebro, 70185, Sweden Less <<
NCT03931291 Acute Myeloid Leukemia or Myel... More >>odysplastic Syndromes Less << PHASE2 COMPLETED 2022-01-14 H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States|Johns Hopkins, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21278, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States Less <<
NCT02999893 Oesophageal Carcinoma PHASE1|PHASE2 TERMINATED 2021-02-07 Monash Medical Centre, Clayton... More >>, Victoria, 3000, Australia|Austin Health, Heidelberg, Victoria, 3000, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3002, Australia|Alfred Hospital, Prahran, Victoria, 3000, Australia|Sunshine Hospital Western Health, Sunshine, Victoria, 3000, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.02mL

1.00mL

0.50mL

25.09mL

5.02mL

2.51mL

50.19mL

10.04mL

5.02mL

References

 

Historical Records

Categories